Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

1.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).

Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F; Cancer and Leukemia Group B.

J Transl Med. 2012 Dec 10;10:246. doi: 10.1186/1479-5876-10-246.

PMID:
23228035
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.

Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM.

Blood. 2003 Dec 15;102(13):4527-34. Epub 2003 Aug 28.

PMID:
12947010
[PubMed - indexed for MEDLINE]
Free Article
3.

Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF.

Blood. 2007 Sep 15;110(6):1982-8. Epub 2007 Jun 1.

PMID:
17545504
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH.

Clin Cancer Res. 2003 Jul;9(7):2520-6.

PMID:
12855626
[PubMed - indexed for MEDLINE]
Free Article
5.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J.

Blood. 2001 Jun 1;97(11):3361-9.

PMID:
11369625
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ.

J Clin Oncol. 2003 Apr 1;21(7):1301-6.

PMID:
12663718
[PubMed - indexed for MEDLINE]
Free Article
7.

HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.

Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH.

Cancer Res. 2006 Jul 1;66(13):6756-62.

PMID:
16818651
[PubMed - indexed for MEDLINE]
Free Article
8.

R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.

Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.

J Cell Physiol. 2007 May;211(2):533-43.

PMID:
17192846
[PubMed - indexed for MEDLINE]
9.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM.

Blood. 2004 May 1;103(9):3271-7. Epub 2004 Jan 15.

PMID:
14726402
[PubMed - indexed for MEDLINE]
Free Article
10.

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H.

Blood. 2003 Mar 1;101(5):1692-7. Epub 2002 Oct 31.

PMID:
12411300
[PubMed - indexed for MEDLINE]
Free Article
11.

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.

PMID:
20944654
[PubMed - indexed for MEDLINE]
Free Article
12.

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH.

Blood. 2011 Nov 3;118(18):4882-9. doi: 10.1182/blood-2011-02-334904. Epub 2011 Jul 1.

PMID:
21725056
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.

Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ.

Cancer. 2005 May 15;103(10):2035-41.

PMID:
15812833
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
[PubMed - indexed for MEDLINE]
Free Article
15.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG.

J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7.

PMID:
18390968
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

Caponigro F.

Anticancer Drugs. 2002 Sep;13(8):891-7.

PMID:
12394276
[PubMed - indexed for MEDLINE]
17.

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA.

Cancer Res. 2010 Nov 1;70(21):8736-47. doi: 10.1158/0008-5472.CAN-10-0902. Epub 2010 Oct 19.

PMID:
20959481
[PubMed - indexed for MEDLINE]
Free Article
18.

Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.

Porcu G, Parsons AB, Di Giandomenico D, Lucisano G, Mosca MG, Boone C, Ragnini-Wilson A.

Mol Cancer. 2013 Aug 6;12(1):88. doi: 10.1186/1476-4598-12-88.

PMID:
23915247
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.

Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P.

Int J Cancer. 2007 Nov 15;121(10):2317-30. Erratum in: Int J Cancer. 2008 Apr 15;122(8):1922.

PMID:
17657738
[PubMed - indexed for MEDLINE]
20.

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ.

Cancer Chemother Pharmacol. 2004 Jun;53(6):513-8. Epub 2004 Feb 3.

PMID:
14760509
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk